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ARTICLE
TRPV4 disrupts mitochondrial transport and
causes axonal degeneration via a CaMKII-
dependent elevation of intracellular Ca2+
Brian M. Woolums1,2, Brett A. McCray2, Hyun Sung2, Masashi Tabuchi 2, Jeremy M. Sullivan2,
Kendra Takle Ruppell3, Yunpeng Yang2, Catherine Mamah2, William H. Aisenberg2, Pamela C. Saavedra-Rivera2,
Bryan S. Larin2, Alexander R. Lau2, Douglas N. Robinson1,4, Yang Xiang3, Mark N. Wu2,5,
Charlotte J. Sumner 2,5✉ & Thomas E. Lloyd 2,5✉
The cation channel transient receptor potential vanilloid 4 (TRPV4) is one of the few iden-
tified ion channels that can directly cause inherited neurodegeneration syndromes, but the
molecular mechanisms are unknown. Here, we show that in vivo expression of a neuropathy-
causing TRPV4 mutant (TRPV4R269C) causes dose-dependent neuronal dysfunction and
axonal degeneration, which are rescued by genetic or pharmacological blockade of TRPV4
channel activity. TRPV4R269C triggers increased intracellular Ca2+ through a Ca2+/calmo-
dulin-dependent protein kinase II (CaMKII)-mediated mechanism, and CaMKII inhibition
prevents both increased intracellular Ca2+ and neurotoxicity in Drosophila and cultured pri-
mary mouse neurons. Importantly, TRPV4 activity impairs axonal mitochondrial transport,
and TRPV4-mediated neurotoxicity is modulated by the Ca2+-binding mitochondrial GTPase
Miro. Our data highlight an integral role for CaMKII in neuronal TRPV4-associated Ca2+
responses, the importance of tightly regulated Ca2+ dynamics for mitochondrial axonal
transport, and the therapeutic promise of TRPV4 antagonists for patients with TRPV4-related
neurodegenerative diseases.
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Congenital distal spinal muscular atrophy (CDSMA), sca-puloperoneal spinal muscular atrophy (SPSMA), andCharcot-Marie-Tooth disease type 2C (CMT2C) are
inherited degenerative diseases of the peripheral nervous system
caused by mutations in the gene encoding the transient receptor
potential vanilloid 4 (TRPV4) cation channel1–3. Peripheral nerve
degeneration in these disorders results in muscle weakness, par-
ticularly of limb, diaphragm, and vocal fold muscles, the latter of
which can be life threatening. They are strikingly variable in
severity, ranging from severe, congenital onset to mild, late adult
onset. The mutations are dominantly inherited missense muta-
tions and each is capable of causing a wide spectrum of disease
severities even within the same family.
TRPV4 is a cell surface-expressed, non-selective cation channel
that is preferentially permeable to Ca2+ and is activated by
mechanical, osmotic, and chemical stimuli4. The majority of
neuropathogenic mutations are present in the intracellular
amino-terminal ankyrin repeat domain1–3,5,6, where it has been
postulated that they may alter inter- or intra-protein–protein
interactions. The consequences of mutations of TRPV4 have been
studied in cultured cells with conflicting results. Some studies
suggest that neuropathy-causing mutations lead to a gain of
TRPV4 ion channel function1,2,5,6, whereas others argue they
cause a loss of function3. No studies have yet examined the effects
of neuropathy-causing TRPV4 mutations on neurons in vivo.
Establishing the pathogenic mechanisms of TRPV4 mutations has
particular relevance for therapeutics development, as small
molecule TRPV4 antagonists have proven safe in human clinical
trials7 and could be repurposed for neurological disease
indications.
There are very few examples of ion channels that are directly
implicated in the process of neurodegeneration, as most neuro-
logical disease-associated channelopathies are paroxysmal dis-
orders such as epilepsy or migraine8. Investigating how TRPV4
mutations cause peripheral neuropathy provides an opportunity
to understand the molecular events linking an ion channel and
Ca2+ homeostasis to the process of neurodegeneration. Although
Ca2+ homeostasis is dysregulated in many neurodegenerative
disorders, it is unknown whether Ca2+ dysregulation is a primary
or secondary pathological event.
Ca2+ regulates both the initiation of fast axonal transport as
well as sustained transport of cargos along axons9,10, and dis-
ruptions of axonal transport are implicated in many neurode-
generative diseases, particularly peripheral nerve disease11,12.
Several forms of hereditary neuropathy are caused by mutations
in genes encoding proteins that regulate axonal transport such
as kinesin (KIF5A), dynein (DYNC1H1), and neurofilament
(NEFL)12. Moreover, the most common form of axonal CMT is
caused by mutations of mitofusin 2 (MFN2), which are associated
with impaired axonal transport of mitochondria13–15. Interroga-
tion of the cellular events underlying TRPV4-associated neuro-
pathy may provide insights into mechanistic links between Ca2+
and impaired axonal transport in neurodegenerative disease.
In this study, we explored the consequences of mutant TRPV4
expression in Drosophila and cultured primary mammalian
neurons. We show that mutant TRPV4 causes neuronal dys-
function and degeneration that are dependent on TRPV4 channel
activity. Using an unbiased forward genetic screen in Drosophila,
we found that TRPV4-mediated increases in intracellular Ca2+
require CaMKII, revealing a central role for CaMKII in TRPV4-
associated axonal degeneration. Moreover, we observe axonal
mitochondrial transport defects downstream of TRPV4 channel
activation. Our data suggest that neuropathogenic TRPV4
mutations sensitize the TRPV4 ion channel resulting in CaMKII-
dependent Ca2+ entry that both disrupts mitochondrial axon
transport and causes axonal degeneration.
Results
TRPV4 mutations disrupt neuron function via the TRPV4
pore. Human TRPV channel expression rescues phenotypes
resulting from loss-of-function mutations in Drosophila TRPV
channels, demonstrating functional conservation across species16.
To evaluate neuropathogenic TRPV4 mutations in vivo, we gen-
erated transgenic Drosophila lines that express human TRPV4
under the control of the GAL4/UAS binary expression system. We
primarily utilized three TRPV4 variants in our studies: wild type
TRPV4 (TRPV4WT), a neuropathy-causing mutant (TRPV4R269C),
and TRPV4R269C with a second engineered mutation known to
block the TRPV4 ion-conducting pore (TRPV4R269C+M680K)
(Fig. 1a)1. We identified low-, moderate-, and high-expressing
transgenic lines (TRPV4(low), TRPV4(mod), and TRPV4(high)) in
which these three variants are expressed at similar levels (Fig. 1b, c,
Supplementary Fig. 1a, b). When expressed in all neurons using the
C155-GAL4 driver, flies expressing TRPV4R269C, but not
TRPV4WT or TRPV4R269C+M680K, fail to appropriately expand
their wings after eclosion (Supplementary Fig. 1c). This phenotype
is dose-dependent, as high-level expression of TRPV4R269C mark-
edly increases the penetrance of the wing phenotype (Supplemen-
tary Fig. 1c). A second neuropathy-causing mutant (TRPV4R232C)
also causes this wing expansion phenotype (Supplementary Fig. 1c),
suggesting that this phenotype is common to neuropathy-
associated variants.
Drosophila wing expansion is controlled by crustacean
cardioactive peptide-expressing neurons (NCCAP), which initiate
motor programs upon eclosion that drive wing expansion17,18.
Selective expression of TRPV4R269C(mod) in these neurons using
CCAP-GAL4 recapitulates the unexpanded wing phenotype
observed with pan-neuronal expression (Fig. 1d, e). Flies
expressing TRPV4R269C+M680K have no wing phenotype, even
with high-level pan-neuronal expression (Fig. 1d, e, Supplemen-
tary Fig. 1c). Furthermore, co-expression of TRPV4R269C+M680K
(mod) strongly suppresses the phenotype caused by TRPV4R269C
(mod), suggesting that the pore-inactivating mutation blocks
channel function both in cis and in trans (Fig. 1e), consistent with
the known tetrameric structure of TRPV4 ion channels19.
TRPV4 mutations are associated with congenital onset disease
in humans, but also with later onset, slowly progressive symptoms.
To assess whether mutant TRPV4 can cause progressive disease
after adult development, we utilized an inducible pan-neuronal
GAL4 driver elav-GeneSwitch (elavGS)20 to express TRPV4(high)
variants in early adulthood. Flies induced to express TRPV4R269C
(high) by feeding with RU486 show a marked, progressive decline
in climbing performance and are unable to climb 12 days after
induction of expression (Fig. 1f). In contrast, flies expressing either
TRPV4WT(high) or TRPV4R269C+M680K(high) show no difference
in climbing performance compared with flies carrying elavGS
alone (Fig. 1f). Together, these data demonstrate that TRPV4R269C
expression can cause both early- and late-onset neuronal
dysfunction in vivo, and that this neurotoxicity requires a
functional ion channel pore.
TRPV4R269C causes axonal and dendritic degeneration.
Degeneration and loss of peripheral nerve axons are characteristic
pathological features of CMT21. To test whether TRPV4R269C
causes neuronal degeneration, we assessed class IV larval den-
dritic arborization (C4da) neurons, sensory neurons with den-
drites that tile the Drosophila larval body wall22, in wandering
third instar larvae using ppk-GAL423. We selected these neurons
for functional and morphological analysis owing to their genetic
tractability, experimental accessibility, and their previous use in a
Drosophila model of CMT24. As compared with control flies
expressing TRPV4WT(high), TRPV4R269C+M680K(high), or no
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TRPV4, flies expressing TRPV4R269C(high) show a marked
loss of C4da neuron axonal projections into the ventral nerve
cord (Fig. 2a, b) and severely reduced dendritic arborizations
within the body wall (Fig. 2c, d). These phenotypes are not
observed with overexpression of other cation channels previously
shown to activate or silence Drosophila neurons and disrupt
NCCAP function18,25 (Supplementary Fig. 2a, c), suggesting these
axonal and dendritic degeneration phenotypes are not caused by
altered neuronal activity.
To determine whether the morphological changes in C4da
neurons are owing to degeneration or impaired development, we
imaged C4da neuron axonal projections and dendrites in larvae at
96 hours (late second instar) and 120 hours (early third instar)
after egg laying (AEL). At 96 hours AEL, we observe no
significant differences in either axonal projections or number
of dendritic branches (Supplementary Fig. 3a, c). However, at
120 hours AEL, we observe axonal swellings (Supplementary
Fig. 3a, 2× zoom, green arrows), fragmentation of distal axonal
a
Proline rich 
Ankyrin repeat 
Transmembrane 
d
fe
%
 A
ni
m
al
s 
w
ith
ab
no
rm
al
 w
in
gs
0.0
0.2
0.4
0.6
0.8
1.0
elavGS
elavGS>TRPV4WT
elavGS>TRPV4R269C
elavGS>TRPV4R269C+M680K
F
ra
ct
io
n 
of
 fl
ie
s
cl
im
bi
ng
 a
bo
ve
 8
 c
m
1 127530
CCAP-GAL4 
b
–100 kDa
– 42 kDa
Anti-TRPV4
Anti-β-actin
C155-GAL4 ipsum
UAS-TRPV4: None WT R269C
R269C+
M680K
CCAP-GAL4 CCAP>TRPV4WT CCAP>TRPV4R269C
CCAP>
TRPV4R269C+M680K
c
Days on 200 μM RU486
UAS-LacZ:
UAS-TRPV4 (1):
UAS-TRPV4 (2):
–
– – – – – –
–– – – – –+
–
–
– +
WT R269C R269C R269C R269C R269CR269C+
M680K
WT
R269C+
M680K
0
50
100
Domains
R269C
M680K
1 871
Ion channel pore 
2.0
1.5
1.0
0.5
0.0
N
or
m
al
iz
ed
T
R
P
V
4/
ac
tin
 in
te
ns
ity
TRPV4: WT R269C R269C+
M680K
Fig. 1 A neuropathy-causing TRPV4 variant causes channel pore-dependent neuronal dysfunction in Drosophila. a Schematic of TRPV4 domain
structure with neuropathy-causing (R269C) and pore-inactivating (M680K) mutations indicated. b Representative western blot of protein lysates from the
heads of adult Drosophila expressing TRPV4(mod) variants under the control of C155-GAL4. c Normalized mean ± SEM band intensities from three
independent western blots. One-way ANOVA (p= 0.778). d Images of flies expressing no TRPV4, TRPV4WT(mod), TRPV4R269C(mod), and TRPV4R269C
+M680K(mod) in NCCAP. e Percentage ± 95% CI of flies with unexpanded wings in d. From left to right n= 115, 102, 73, 64, 82, 114, 75, 45, and 61 flies. Χ2 of
all groups (p < 0.0001) followed by pairwise two-sided Fisher’s exact test. f Climbing performance of flies inducibly expressing TRPV4 (high) variants. Flies
induced at 1–3 days post eclosion with 200 μM RU486. Mean ± SEM. n= 10 vials of 10 flies per genotype. Two-way ANOVA (p < 0.0001), Tukey’s post
hoc test, asterisks indicate difference from all other genotypes. For all panels: ****p < 0.0001.
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projections (Supplementary Fig. 3a, 2× zoom, magenta arrow),
and a reduction of dendritic branching (Supplementary Fig. 3b, c)
in larvae expressing TRPV4R269C (high). Like the phenotypes in
NCCAP, axonal degeneration in C4da neurons is TRPV4-dosage
dependent, as moderate expression of TRPV4R269C does not alter
axonal projection area (Supplementary Fig. 3d, e). Of note, high
expression (but not moderate expression) of TRPV4WT causes a
mild wing expansion phenotype and a mild loss of axonal
projections and dendritic branching (Supplementary Fig. 1c,
Fig. 2a, b). Thus, TRPV4R269C causes neurodegeneration in vivo
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Fig. 2 High TRPV4R269C expression disrupts C4da neuron axonal and dendritic projections. Confocal projections of C4da neuron axonal projections a and
dendrites c from wandering third instar larvae expressing TRPV4 (high) variants. b Mean ± SEM normalized projection areas in a. n= 9 (control), 9
(TRPV4WT), 10 (TRPV4R269C), and 9 (TRPV4R269C+M680K) larvae. Two-way ANOVA (p < 0.0001), Tukey’s post hoc test. d Sholl analysis of neurons in c.
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Tukey’s post hoc test. Confocal stacks of axonal projections e and dendrites f of flies expressing TRPV4R269C(high) raised on food with either DMSO or 100 μM
GSK219. g Sholl analysis of dendritic phenotypes in f. Control from d shown for reference. Mean ± SEM. n= 6 cells from three larvae for DMSO, n= 10 cells
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in a dose-dependent manner, and sufficient expression of
TRPV4WT can cause similar, yet more mild, phenotypes. These
observations are consistent with a gain-of-TRPV4 function
mechanism of toxicity caused by the R269C mutation.
TRPV4 antagonists suppress TRPV4-mediated neurodegen-
eration. As genetic inactivation of the TRPV4R269C channel pore
rescues neurotoxicity (Figs. 1d, f, 2a, d, and Supplementary
Fig. 1c), we next asked if TRPV4 could be blocked pharmacolo-
gically to suppress the axonal and dendritic phenotypes mediated
by TRPV4R269C(high). We tested the selective TRPV4 antagonist
GSK2193874 (GSK219) because TRPV4 antagonists are in clinical
development for the treatment of pulmonary edema during heart
failure7,26. Embryos expressing TRPV4R269C were raised on food
containing either GSK219 or DMSO vehicle alone throughout
larval development. Remarkably, GSK219 treatment of
TRPV4R269C(high) flies reduces axonal degeneration and den-
dritic branching defects as compared to vehicle treatment alone
(Fig. 2e, g).
CaMKII is required for TRPV4R269C-mediated neurotoxicity.
To identify genes that contribute to TRPV4R269C-mediated neu-
rotoxicity, we performed RNAi- and overexpression-based
screens for genetic modifiers of the wing expansion phenotype
caused by moderate TRPV4R269C expression in NCCAP. With the
goal of identifying potential therapeutic targets, we specifically
screened genes that are conserved in humans, potentially drug-
gable27, and expressed in the Drosophila nervous system (flybase.
org). We also screened fly orthologues of genes previously
implicated in CMT. In total, we evaluated 692 transgenic lines
covering 502 genes and identified 8 genes that reduce the pene-
trance of the TRPV4R269C-mediated wing phenotype to <25%
compared with the 70–100% penetrance observed in control flies
(Fig. 3a, Supplementary Data 1).
The most potent genetic modifier identified in this screen was
Ca2+/calmodulin-dependent protein kinase II (CaMKII), a key
regulatory kinase of many neuronal signaling pathways28.
Knockdown of the single Drosophila CaMKII using four
independent RNAi lines on three distinct genetic backgrounds
reduces the penetrance of the TRPV4R269C-mediated wing
phenotype to 0–10% (Fig. 3a, c). CaMKII knockdown is also
sufficient to ameliorate other TRPV4R269C-mediated phenotypes
including the loss of C4da neuron axonal projections in flies
expressing TRPV4R269C(high) (Fig. 3d, e) and the climbing
phenotype at 7 days post induction of elavGS (Fig. 3f).
To test whether CaMKII overexpression can enhance
TRPV4R269C-mediated neurotoxicity, we generated a UAS line
that expresses TRPV4R269C at very low levels via site-directed
insertion (TRPV4R269C(low))29. Although overexpression of
either TRPV4R269C(low) or CaMKII alone in NCCAP did not
impair wing expansion, simultaneous overexpression of both
CaMKII and TRPV4R269C(low) causes a highly penetrant wing
phenotype (Fig. 3g). Upon binding Ca2+, CaMKII is autopho-
sphorylated at T287 enabling Ca2+-independent, constitutive
CaMKII activity28. Interestingly, in the absence of TRPV4R269C,
expression of the constitutively active T287D phosphomimetic
mutant of CaMKII30, but not the Ca2+-dependent T287A
mutant, cause a highly penetrant wing phenotype (Fig. 3g).
These data suggest that CaMKII autophosphorylation is necessary
and sufficient to mediate neurotoxicity caused by TRPV4R269C. A
secondary genetic screen examining known CaMKII target
proteins and pathways did not identify individual modifiers that
similarly rescued TRPV4R269C-mediated toxicity, suggesting that
either multiple CaMKII substrates are involved or that CaMKII is
working through an unknown substrate (Supplementary Data 2).
TRPV4R269C causes CaMKII-dependent hyperexcitability.
NCCAP regulate Drosophila wing expansion in a manner that is
sensitive to changes in excitability17,18. To test whether TRPV4
ion channel activity influences the excitability of NCCAP, we uti-
lized whole-cell perforated patch-clamp recording25,31 to measure
the activity of NCCAP in flies expressing TRPV4WT(mod), or
TRPV4R269C(mod). A tracer dye was injected into the neurons
following recording to validate cell identity (Supplementary
Fig. 4). Expression of TRPV4R269C(mod) increases the sponta-
neous mean firing rate of NCCAP by 5.8-fold, compared with an
approximately twofold increase brought about by TRPV4WT
(mod) expression (Fig. 4a, b). In addition, TRPV4R269C(mod)
increases the intrinsic excitability of NCCAP as measured by the
mean firing rate in response to injected current (Supplementary
Fig. 5a). We observe no change in the mean resting membrane
potential (RMP) (Supplementary Fig. 5b), but subthreshold
membrane potential variability (Δ ramp), a property that may
allow neurons to reach threshold more frequently, is increased in
flies expressing TRPV4R269C(mod) (Supplementary Fig. 5c).
To test whether changes in excitability are related to changes in
Ca2+, we applied the cell-permeant Ca2+ chelator 1,2-bis(O-
aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA).
BAPTA application blocks the increased spontaneous mean
firing rate (Fig. 4a, b), intrinsic NCCAP excitability (Supplemen-
tary Fig. 5d) and Δ ramp (Supplementary Fig. 5f) caused by
TRPV4WT(mod) and TRPV4R269C(mod). Similarly, the TRPV4-
selective antagonist GSK219 also reduces spontaneous activity
(Fig. 4c), intrinsic excitability (Supplementary Fig. 5g), and Δ
ramp (Supplementary Fig. 5i) in a dose-dependent fashion, as
does knockdown of CaMKII (Fig. 4d, e, Supplementary Fig. 6a, c).
Collectively, these data demonstrate that reversible alterations of
TRPV4R269C-mediated excitability are dependent on both
intracellular Ca2+ and CaMKII.
TRPV4R269C has enhanced response to agonist stimulation. To
evaluate if TRPV4 activity alters intracellular Ca2+ dynamics in
neurons in vivo, we co-expressed the genetically encoded calcium
indicator GCaMP6s23 with TRPV4(mod) variants in C4da neu-
rons. We analyzed Ca2+ dynamics by measuring changes in
GCaMP6s fluorescence intensity in C4da neuronal somata of
dissected third instar larvae after administration of vehicle or the
TRPV4-selective agonist GSK1016790A (GSK101)32,33. C4da
neurons expressing TRPV4R269C(mod) demonstrate a faster Ca2+
response upon GSK101 application than C4da neurons expres-
sing TRPV4WT(mod), with a time to half maximum intensity
(t1/2 max) of 22 ± 2.4 s (best fit parameter ± SEM) for TRPV4R269C
compared with a t1/2 max of 41 ± 3.0 s for TRPV4WT (p < 0.0001)
(Fig. 5a, b). There is also a trend toward a higher maximum
response in TRPV4R269C-expressing larvae (Fig. 5a, b). Control
C4da neurons expressing no TRPV4 or TRPV4R269C+M680K
show no change in Ca2+ levels in response to GSK101, and no
neurons responded to DMSO treatment alone (Fig. 5a, b, Sup-
plementary Fig. 7a). We also monitored spontaneous calcium
transients in the larval ventral nerve cord using myristoylated
GCaMP5 in C4da neurons expressing TRPV4 variants. Notably,
C4da neurons expressing TRPV4R269C(mod) have a marked
increase in spontaneous calcium transients in axonal projections
compared with control neurons and neurons expressing
TRPV4WT (Supplementary Fig. 7b and Supplementary Videos 1–
3). This increase is abolished by inclusion of the M680K mutation
(Supplementary Fig. 7b and Supplemental Video 4), suggesting
that the increase in calcium transient frequency is TRPV4
channel pore-dependent.
To determine whether similar effects are observed in
mammalian neurons, we cultured primary mouse trigeminal
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neurons and transduced them with equivalent titers of lentiviral
vectors encoding TRPV4WT-EGFP or TRPV4R269C-EGFP (Sup-
plementary Fig. 8a, b). Both TRPV4WT-EGFP and TRPV4R269C-
EGFP express at equivalent levels and localize to the cell cortex in
the somata and neurites (Supplementary Fig. 8c, d). We
determined somal Ca2+ signals by measuring the Fura-2AM
340/380 ratio. As predicted based on calcium imaging of
nonneuronal cells5, there is a small but statistically significant
increase in baseline calcium levels in neurons expressing
TRPV4R269C compared with TRPV4WT (Supplementary Fig. 8e).
e
a
0 25 50 75 10
0
250
200
150
100
50
0
# 
 T
ra
ns
ge
ni
c 
 li
ne
s
Binned % abnormal male flies
b
CCAP-GAL4
c
++ + + +–––––
– W
T
W
T
T
28
7A
T
28
7D
1
T
28
7D
1
T
28
7A
T
28
7D
2
T
28
7D
2
–
UAS-CaMKII
RNAi :
– – –1 2 3 4
Background: A A B B B C C
CaMKII RNAi
0
50
100
%
 F
lie
s 
w
ith
ab
no
rm
al
 w
in
gs
0
50
100
UAS-CaMKII:
UAS-TRPV4R269C
(low):
%
 F
lie
s 
w
ith
 a
bn
or
m
al
 w
in
gs
UAS-CaMKII
RNAi:
pp
k>
C
D
8:
:G
F
P
None None +
UAS-TRPV4R269C
(high):
CCAP>TRPV4R269C (mod)
Control UAS-CaMKII RNAi
– – +
f
d
g
None + +
UAS-TRPV4R269C
(high):
UAS-CaMKII
RNAi:
– + +
0
5
10
15
# 
H
em
is
eg
m
en
ts
w
ith
 ip
si
la
te
ra
l a
xo
ns
0.8
0.6
0.4
0.2
0.0
F
ra
ct
io
n 
of
 fl
ie
s
cl
im
bi
ng
 a
bo
ve
 8
 c
m
elavGS
elavGS>CaMKII RNAi
elavGS>TRPV4R269C
elavGS>TRPV4R269C + CaMKII RNAi
CCAP > TRPV4R269C (mod)
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16411-5
6 NATURE COMMUNICATIONS |         (2020) 11:2679 | https://doi.org/10.1038/s41467-020-16411-5 | www.nature.com/naturecommunications
10 s
20 m
V
a b
c
d
No UAS-CaMKII RNAi +UAS-CaMKII RNAi
[GSK219] nM (TRPV4 antagonist)
e
20 m
V
10 s
CCAP>TRPV4R269C
CCAP>TRPV4R269C
CCAP>TRPV4WT
CCAP-GAL4
+5 mM BAPTA
+5 mM BAPTA
+5 mM BAPTA
0
2
4
6
8
M
ea
n 
fir
in
g 
ra
te
 (
H
z) No TRPV4
TRPV4WT
TRPV4R269C
+BAPTA
0
2
4
6
8
M
ea
n 
fir
in
g 
ra
te
 (
H
z) TRPV4WT
TRPV4R269C
0
10
0
50
00
10
0
50
0
10
,0
00
0
1
2
3
4
5
M
ea
n 
fir
in
g 
ra
te
 (
H
z)
No CaMKII RNAi
+CaMKII RNAi 
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Fig. 3 CaMKII is required for TRPV4R269C-mediated neuronal toxicity. a Histogram of results from genetic modifier screen against TRPV4R269C toxicity
in NCCAP. Dashed magenta lines denote upper and lower bounds of control lines. b Images of flies expressing TRPV4R269C(mod) ± CaMKII RNAi.
c Percentage ± 95% CI of flies with unexpanded wings when co-expressing TRPV4R269C(mod) and different CaMKII RNAi fly lines. A= TRiP collection
lines, B=Vienna GD collection lines, and C=Vienna KK collection lines. From left to right n= 65, 59, 60, 25, 65, 66, and 90 flies. Χ2 test of all groups (p <
0.0001) followed by pairwise two-sided Fisher’s exact test. d Confocal stacks of axonal projections in C4da neurons expressing TRPV4R269C(high) ±
CaMKII RNAi. eMean ± SEM innervation in d. n= 5, 4, and 5 larvae, respectively. One-way ANOVA (p < 0.0002), Tukey’s post hoc test. Scale bar, 25 µm.
f Climbing performance of flies 7 days after induction of expression of TRPV4R269C(high) ± CaMKII RNAi with 200 μM RU486. Mean ± SEM. n= 10 vials
of 10 flies per genotype. Two-way ANOVA (p < 0.0001), Tukey’s post hoc test. g Percentage ± 95% CI of flies with unexpanded wings when co-expressing
TRPV4R269C(low) with variants of CaMKII. T287D1 and T287D2 denote independent UAS-CaMKIIT287D lines. From left to right n= 63, 55, 68, 44, 23, 33,
28, 23, 2, and 3 flies. Χ2 test of all groups (p < 0.0001) followed by pairwise two-sided Fisher’s exact test. For all panels: **p < 0.01, ****p < 0.0001.
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Like fly neurons, mouse trigeminal neurons transduced with
TRPV4R269C-EGFP respond more rapidly and more robustly to
GSK101 with a t1/2 max of 16 ± 3.8 s (best fit parameter ± SEM) as
compared with TRPV4WT (28 ± 8.5 s) (Fig. 5c, d). The maximum
response of TRPV4R269C (1.2 ± 0.016) is greater than that of
TRPV4WT (0.91 ± 0.014) (p < 0.0001). Collectively, these data
indicate that the R269C mutation sensitizes the TRPV4 channel
in Drosophila neurons in vivo and primary mammalian neurons
in vitro, consistent with the gain-of-ion channel function
phenotypes observed in flies.
To determine whether CaMKII is required for TRPV4-induced
Ca2+ influx, we treated primary trigeminal neurons expressing
TRPV4WT-EGFP with the calmodulin-targeting CaMKII inhibi-
tor KN-93 or its inactive analog KN-9234,35. Remarkably, KN-93
significantly attenuates Ca2+ responses to GSK101 in neurons
expressing TRPV4WT-EGFP, whereas those treated with KN-92
TRPV4WT
TRPV4R269C TRPV4R269C + M680K
Control
b
TRPV4R269C
pr
e-
G
S
K
10
1
po
st
-G
S
K
10
1
4095
0
TRPV4WTNone
a
pp
k>
G
C
aM
P
6s
TRPV4
R269C+
M680K
d
 GSK101 (TRPV4 agonist)
primary mouse trigeminal neurons
0 50 100 150 200
1.4
1.2
1.0
0.8
0.6
TRPV4WT-EGFP + 10 μM KN-92 (control)
Time (s)
TRPV4WT-EGFP + 10 μM KN-93 (CaMKII inhibitor)
GSK101 (TRPV4 agonist)e
F
ur
a-
2 
ra
tio
 (
34
0/
38
0)
20 40 60
0.5
1.0
G
C
aM
P
6s
 Δ
 F
/F
 
GSK101 (TRPV4 agonist)
Time (s)
30
 s
12
0 
s
0 
s
tim
e 
af
te
r 
G
S
K
10
1 
ad
di
tio
n
G
C
aM
P
6s
 in
te
ns
ity
TRPV4R269C-EGFPTRPV4WT-EGFP
c
3
0
F
ur
a-
2 
ra
tio
pr
im
ar
y 
m
ou
se
 tr
ig
em
in
al
 n
eu
ro
ns
UAS:
0 100 200
1.6
1.4
1.2
1.0
0.8
0.6
Time (s)
F
ur
a-
2 
ra
tio
 (
34
0/
38
0)
TRPV4WT-EGFP TRPV4R269C-EGFP
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16411-5
8 NATURE COMMUNICATIONS |         (2020) 11:2679 | https://doi.org/10.1038/s41467-020-16411-5 | www.nature.com/naturecommunications
respond normally to agonist stimulation (Fig. 5e). We observe
similar inhibitory effects when treating with autocamtide-2-
related inhibitory peptide (AIP), a small peptide CaMKII
inhibitor36 (Supplementary Fig. 9a). The effect of CaMKII
inhibition is not owing to altered TRPV4 surface expression, as
CaMKII inhibition does not alter the cortical localization of
TRPV4-EGFP (Supplementary Fig. 9b, e). Furthermore, CaMKII
inhibition with KN-93 also prevents increases of intracellular
Ca2+ levels mediated by endogenous TRPV4 in an immortalized
rat dorsal root ganglion cell line37 (Supplementary Fig. 10a, c).
These data indicate that CaMKII is required for TRPV4-mediated
increases in intraneuronal Ca2+ levels.
TRPV4R269C disrupts mitochondrial axon transport. Axonal
transport of mitochondria is regulated by intracellular Ca2+ 9,10,38.
To assess mitochondrial axon transport dynamics, we imaged the
proximal axon of C4da neurons co-expressing TRPV4(mod) var-
iants and the mitochondrial reporter mito-GFP. We used the
TRPV4R269C(mod) line as it does not exhibit observable morpho-
logical phenotypes in C4da neuron axons or their central projec-
tions (Supplementary Fig. 3d, e). TRPV4R269C(mod) expression
significantly inhibits mitochondrial axon transport compared with
controls expressing no TRPV4, whereas TRPV4WT(mod) and
TRPV4R269C+M680K(mod) has minimal impact. Specifically, both
anterograde and retrograde axonal mitochondria are more often
stationary (Fig. 6a, c), and retrograde more than anterograde
mitochondria have shorter run lengths (Fig. 6d, e).
To test whether pharmacologic activation of TRPV4WT is
sufficient to disrupt mitochondrial transport dynamics,
TRPV4WT(mod) larvae were treated with GSK101. This results
in an increased proportion of stationary mitochondria and
reduced run length similar to that observed in animals expressing
TRPV4R269C(mod) alone (Fig. 7a, b, Supplementary Fig. 11a, b
and d, e). Interestingly, larvae expressing TRPV4R269C exhibit
minimal further disruption of mitochondrial transport in
response to GSK101 (Supplementary Fig. 11c, f), possibly owing
to saturation of the molecular machinery responsible for
inhibiting transport. We also tested whether treating
TRPV4R269C(mod)-expressing larvae with the TRPV4-selective
antagonist GSK219 can ameliorate mitochondrial transport
defects. GSK219 normalizes the proportion of motile mitochon-
dria (Fig. 7c, d) and causes a shift to longer retrograde run lengths
in TRPV4R269C-expressing larvae, but not control larvae
(Supplementary Fig. 11g–j). These data indicate that TRPV4
activation, induced either by the R269C mutation or by a
pharmacological agonist, disrupts mitochondrial axon transport.
Miro modifies TRPV4R269C-mediated toxicity. Notably, the
TRPV4-mediated axonal mitochondrial transport phenotypes
(Figs. 6, 7a–b) are similar to those seen in Drosophila larvae with
homozygous loss-of-function mutations of mitochondrial Rho
(Miro)39,40. Miro is a Ca2+-binding GTPase that localizes to the
outer membrane of mitochondria and regulates mitochondrial
coupling to microtubule motors38,41,42. Miro binds Ca2+ via two
EF hand domains, and this Ca2+ binding promotes the dis-
sociation of mitochondria from the microtubule motor or
microtubule. The amino-terminal GTPase domain of Miro is
required for appropriate transport of mitochondria along
axons39,40,43, though the specific function of this domain remains
unknown. To test whether Miro and TRPV4 function in a
common pathway, we tested for genetic interactions between
TRPV4R269C and Miro variants in NCCAP and C4da neurons.
While TRPV4R269C(low) or wild type Miro do not cause a wing
phenotype when expressed individually, co-expression of both
Miro and TRPV4R269C(low) cause an ~40% penetrant wing
phenotype (Fig. 7e). Interestingly, expression of a GTP-bound
Miro mutant (MiroA20V) alone is sufficient to cause impaired
wing expansion, and this phenotype is not enhanced by co-
expression of TRPV4R269C (Fig. 7e). Similarly, co-expression of
MiroWT or MiroA20V together with TRPV4R269C(mod) causes
axonal degeneration in C4da neurons (Fig. 7f). Overexpression of
MiroWT alone only mildly alters C4da neuron central projections,
whereas MiroA20V alone is sufficient to cause axonal degeneration
(Supplementary Fig. 12a). In contrast, expression of a Miro var-
iant locked in the GDP-bound confirmation (MiroT25N) sup-
presses the TRPV4R269C(mod)-mediated wing phenotype and
does not cause NCCAP toxicity when co-expressed with
TRPV4R269C(low) (Supplementary Fig. 12b). In addition,
expression of MiroT25N suppresses axonal degeneration in C4da
neurons induced by TRPV4R269C(high) and does not cause
toxicity in C4da neurons when co-expressed with TRPV4R269C
(mod) (Supplementary Fig. 12c–d). These data suggest that GTP
binding of the amino-terminal GTPase domain of Miro is
necessary and sufficient to promote neurotoxicity downstream of
TRPV4 activation.
Notably, these genetic interactions are not observed in NCCAP
with Miro variants unable to bind Ca2+ (MiroE234K or
MiroE234K+E354K) (Fig. 7e). Moreover, Miro variants that
cannot bind Ca2+ do not induce C4da axonal degeneration
when co-expressed with TRPV4R269C(mod) (Fig. 7f). Thus,
Miro-mediated enhancement of TRPV4R269C-dependent axo-
nal degeneration is dependent on the ability of Miro to bind
Ca2+, suggesting that TRPV4R269C causes axonal degeneration
by promoting the binding of Ca2+ to Miro.
Discussion
Inherited motor and sensory peripheral neuropathy, also known
as CMT, is the most common form of genetically determined
neuromuscular disease21. Despite the identification of over 100
causative genes, treatment remains elusive. TRPV4 is one of the
Fig. 5 The R269C mutation enhances TRPV4-mediated Ca2+ influx in fly and mouse neurons. a Confocal images of GCaMP6s in larval C4da neurons
expressing the indicated transgenes before and 180 s after application of 40 nM GSK101 at t=0 s. Scale bar, 50 μm. b Change in somal GCaMP6s fluorescence
over baseline (ΔF/F) of the genotypes shown in a. Mean ± SEM. n= 8 (no TRPV4), 8 (TRPV4WT), 7 (TRPV4R269C) and 10 (TRPV4R269C+M680K). Non-linear
regression (dashed lines, logistic model) indicates TRPV4WT t1/2max= 41 ± 3.0 s was greater than TRPV4R269C t1/2max= 22 ± 2.4 s (p < 0.0001, unpaired two-
tailed t test). Maximum response 0.91 (TRPV4R269C) and 0.73 (TRPV4WT) (p=0.06, unpaired two-tailed t test) c Images of the Fura-2AM ratio in primary
mouse trigeminal neurons transduced with TRPV4WT or TRPV4R269C before and after the application of 30 nM GSK101. Scale bar, 50 μm. dMean ± SEM Fura-
2AM ratio over time of the images in c. Drug added at t=0. n= 44 (TRPV4WT) and 48 (TRPV4R269C) neurons from 12 wells per genotype from three separate
preparations. Non-linear regression (dashed lines, logistic model) indicates TRPV4WT t1/2max= 28 ± 8.5 s and TRPV4R269C t1/2max = 16 ± 3.8 s (p=0.2,
unpaired two-tailed t test). Maximum responses TRPV4WT=0.9, TRPV4R269C= 1.2 (p < 0.0001, unpaired two-tailed t test). e Mean ± SEM Fura-2AM ratio
over time in response to 30 nM GSK101 at t=0 in neurons expressing TRPV4WT and pre-treated for 4 hours with 10 μMKN-93 or KN-92, n= 44 (KN-92) and
28 neurons (KN-93) from 12 wells per genotype from three separate preparations. Two-way ANOVA, Geisser-Greenhouse correction (p < 0.0001), Tukey’s
post hoc test. For all panels: *p < 0.05,**p < 0.01, ***p < 0.001.
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rare ion channels that can directly cause peripheral nerve
degeneration1–3, yet the mechanisms leading to neuronal dys-
function are unknown. In this study, we demonstrate in Droso-
phila and primary mammalian neurons that a neuropathy-
causing mutant, TRPV4R269C, causes neurodegeneration and
increases intraneuronal Ca2+ via a mechanism that requires a
functional ion channel pore (Supplementary Fig. 13). In a genetic
screen, we identified CaMKII, a Ca2+-dependent kinase, as a
potent modifier of TRPV4R269C-mediated neurotoxicity, unveil-
ing an important role for CaMKII in neuronal TRPV4-associated
Ca2+ signaling. Futhermore, we show that impaired mitochon-
drial trafficking and the Ca2+-binding protein Miro are
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important determinants of neurotoxicity downstream of TRPV4
activity.
Dominant missense mutations in TRPV4 cause a spectrum of
in vivo neuropathies that can present congenitally or late in
adulthood1–3. In this study, we observed cell-autonomous
neuronal dysfunction and/or degeneration in multiple Drosophila
neuronal subtypes as a consequence of expressing a neuro-
pathogenic mutant form of TRPV4. These phenotypes manifest
as early as late larval developmental stages, when abnormalities in
neuronal development or maintenance may be relevant, but we
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also demonstrate that mutant TRPV4 expression can cause adult
onset, progressive neuronal dysfunction. Phenotype severity is
dependent on TRPV4 expression levels, suggesting that variations
in the timing and/or level of TRPV4 expression may be relevant
determinants of the marked disease heterogeneity observed in
patients.
Neuronal dysfunction and degeneration caused by neuro-
pathogenic TRPV4 mutants in vivo were dependent on a func-
tional channel pore, consistent with a gain-of-function
mechanism of toxicity. These observations are consistent with
prior data in cultured cell lines1,2,5,6 and the lack of neurode-
generative phenotypes in Trpv4-null mice44,45. Furthermore,
small molecule inhibition of TRPV4 ameliorates TRPV4-
mediated phentoypes in Drosophila, suggesting that TRPV4
antagonism is a promising therapeutic strategy for the treatment
of patients with TRPV4-associated neuropathies. TRPV4 inhibi-
tion has also been shown to be protective in rodent models of
chemotherapy-induced peripheral neuropathy46,47, suggesting
that TRPV4 antagonists may have utility in peripheral neuro-
pathies of diverse etiologies. This is particularly exciting as small
molecule TRPV4 antagonists have already proven to be safe in
clinical trials for pulmonary edema in heart failure7.
Our study highlights that increased intracellular Ca2+ is a
fundamental consequence of TRPV4R269C activation in Droso-
phila neurons in vivo and in mammalian neurons in vitro. Tightly
regulated Ca2+ homeostasis is critical to myriad aspects of nor-
mal neuronal physiology and may be disrupted during neuro-
degeneration. To identify specific pathways acting downstream of
TRPV4R269C, we conducted, to our knowledge, the largest genetic
modifier screen in a Drosophila model of CMT and identified
CaMKII as the most potent modifier. We further demonstrated
that inhibition of CaMKII ameliorates multiple mutant TRPV4-
mediated neuronal phenotypes in flies and also dramatically
suppresses TRPV4-mediated intracellular Ca2+ responses in
mammalian neurons.
CaMKII is a critical Ca2+-sensitive kinase that transduces
changes in intracellular Ca2+ to regulate diverse neuronal pro-
cesses, including neurite morphogenesis, neuronal excitability,
synaptic plasticity, and ion channel activity28,48. We envision two
possible mechanisms by which CaMKII influences TRPV4-
mediated increases in intracellular Ca2+. First, CaMKII could
directly modulate TRPV4 channel gating. Indeed, the gating
properties of ion channels such as AMPA receptors can be
strongly modulated by CaMKII-dependent phosphorylation49.
CaMKII is a putative binding partner of TRPV450,51, consistent
with the possibility that TRPV4 is directly regulated by CaMKII,
but, to our knowledge, no CaMKII-dependent phosphorylation
sites in TRPV4 have been identified.
A second potential mechanism is that activation of CaMKII by
TRPV4-mediated Ca2+ influx could regulate subsequent TRPV4-
independent Ca2+ release, either by opening of Ca2+-permeable
channels within the plasma membrane or by activating release of
intracellular Ca2+ stores. Several studies suggest that
TRPV4 stimulation orchestrates activation of Ca2+-sensitive
plasma membrane channels that amplify and propagate Ca2+
signaling events, and some of these responses can be modulated
by inhibition of CaMKII52–57. In addition, TRPV4-mediated
intracellular Ca2+ responses can be blunted by depleting endo-
plasmic reticulum (ER) Ca2+ stores or by inhibiting ER Ca2+
release channels, suggesting amplification of signaling by Ca2+
-mediated ER Ca2+ release58–60. CaMKII can phosphorylate and
regulate mammalian IP3 receptors and ryanodine receptors61
potentially linking activation of CaMKII with downstream ER
Ca2+ release. Notably, our secondary genetic screen found partial
suppression of the wing expansion phenotype with RNAi tar-
geting the Drosophila ryanodine receptor (RyR) (Supplementary
Data 2). Regardless of the mechanism by which CaMKII influ-
ences TRPV4-mediated intracellular Ca2+ elevations, our results
highlight CaMKII as a potent modifier of TRPV4-mediated Ca2+
signaling and toxicity and add to the growing body of evidence
underscoring key roles for CaMKII in neuronal Ca2+ homeostasis
and degeneration62–64.
Transport of mitochondria within axons is a Ca2+-regulated
process that is crucial to neuronal homeostasis. Disrupted mito-
chondrial transport is a common feature across many neurode-
generative diseases, although whether such disruption is an early
pathogenic process or a reflection of non-specific neuronal dys-
function is unclear11,12. In this study, we observed mitochondrial
transport defects downstream of neuropathogenic TRPV4 activity
prior to the onset of observable degeneration, suggesting that
mitochondrial transport impairments are an early pathological
event. In addition, mitochondrial transport is impaired by acute
activation of TRPV4WT, demonstrating a close temporal asso-
ciation between TRPV4 activation and impaired mitochondrial
transport. As increased intracellular Ca2+ is sufficient to inhibit
the axonal transport of mitochondria38, our data are consistent
with a model in which TRPV4-mediated Ca2+ influx serves to
regulate the function of axonal mitochondrial transport
machinery. In animal models of chemotherapy-induced neuro-
pathy, in which mitochondrial trafficking defects are well-estab-
lished, inhibition of TRPV4 activity is partially protective46,47.
Our results suggest that blocking TRPV4-mediated disruption of
mitochondrial transport may be the mechanism for this protec-
tive effect.
Our data highlight the importance of the mitochondrial
GTPase Miro, which regulates mitochondrial transport in fly and
mammalian neurons via mechanisms that rely on the Ca2+
-binding EF hand domains and amino-terminal GTPase domain,
and suggest that Miro provides the link between TRPV4-
mediated Ca2+ elevations and disrupted mitochondrial trans-
port38–40,43. We observe a marked enhancement of TRPV4R269C-
mediated neurotoxicity by overexpression of wild type Miro, but
Fig. 7 Pharmacologic manipulation of TRPV4 modulates mitochondrial transport and the mitochondrial transport protein Miro enhances TRPV4R269C-
mediated toxicity. a Kymographs of mito-GFP transport in C4da neuron proximal axons in larvae expressing no TRPV4, TRPV4, or TRPV4R269C treated
with 40 nM GSK101 or DMSO. Scale bar, 10 μm. b Fraction of stationary, anterograde-, and retrograde-moving mitochondria from a. Mean ±SEM. For
control, TRPV4WT, and TRPV4R269C: DMSO n= 9, 10, 10 larvae; GSK101 n= 10, 14, 11 larvae. Two-way ANOVA (p < 0.0001), Tukey’s post hoc test.
c Kymographs of mito-GFP transport in C4da neuron axons in larvae expressing no TRPV4 or TRPV4R269C raised on food containing DMSO or 100 µM
GSK219 and treated with 10 µM GSK219 during imaging. Scale bar, 10 μm. d Percentage of stationary, anterograde-, and retrograde-moving mitochondria
from c. Mean ± SEM. For control and TRPV4R269C: DMSO n= 11 and 12 larvae; GSK219 n= 14 and 13. Two-way ANOVA (p < 0.0001), Tukey’s post hoc
test. e Percentage ± 95% CI of flies with unexpanded wings when expressing Miro variants ± TRPV4R269C(low) in NCCAP. From left to right n= 86, 72, 64,
77, 62, 54, 33, 38, 32, 39, 35, and 41 flies. Χ2 test (p < 0.0001) followed by pairwise two-sided Fisher’s exact test. f Representative confocal images of C4da
neuron projections in larvae expressing TRPV4R269C(mod) (as in Supplementary Fig. 2d and e) ± overexpressed Miro variants. Similar results observed in
all imaged larvae within each genotype (n= 7, 8, 8, 8, 7, 8, and 8 larvae from left to right) Scale bar, 25 μm. For all panels: *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001.
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not by Miro that is unable to bind Ca2+, and the GTP-bound
form of Miro recapitulates both the wing-opening failure and
sensory neuron degenerative phenotypes, independent of TRPV4
expression. Together, these results suggest that dysregulation of
Miro is a fundamental downstream effect of TRPV4 activation, as
Miro disruption is both necessary and sufficient for the neuronal
phenotypes we observe in our TRPV4 fly model. These results are
in agreement with prior work highlighting the critical importance
of Miro for neuronal health and survival. miro-null flies exhibit
severe mitochondrial axon transport defects and early lethality39,
whereas Miro1-null mice have degenerative motor neuron
disease65.
Our results linking mitochondrial trafficking impairment and
neuronal degeneration closely parallel findings in animal models
harboring MFN2 mutations that cause CMT2A. Similar to Miro,
MFN2 has myriad roles in mitochondrial biology, and pathogenic
MFN2 mutations result in defective mitochondrial fusion and
transport14,15,66. MFN2 agonists restore mitochondrial trafficking
defects in pre-clinical models of CMT2A67, thus establishing a
precedent for correcting defects similar to those reported in this
study through small molecule manipulation of a mitochondrial
GTPase. Moreover, a recent study suggests that CMT2 mutations
in both MFN2 and TRPV4 prolong inter-mitochondrial con-
tacts68. Further investigation of functional interactions between
TRPV4 and mitochondrial biology will help elucidate the precise
contributions of these potential pathological mechanisms and
could refine therapeutic strategies for a range of neuropathies.
In summary, our data support a model in which neuropatho-
genic TRPV4 mutants cause cell-autonomous neurotoxicity
through a gain-of-TRPV4 ion channel function. This results in a
CaMKII-dependent increase in neuronal Ca2+ that disrupts
mitochondrial transport and causes axonal degeneration (Sup-
plementary Fig. 13). These phenotypes are prevented by TRPV4
antagonists, which hold promise as a therapeutic strategy for the
treatment of patients with TRPV4-associated neuropathies.
Methods
Drosophila stocks and husbandry. Flies were raised on a standard cornmeal-
molasses food. All experiments were performed at 25 °C with a 12 hour/12 hour
day/night cycle, unless otherwise noted. The following stocks were obtained from
the Bloomington Stock Center: UAS-CD8::GFP, UAS-mito-GFP, ppk-GAL4,
CCAP-GAL4, UAS-GCaMP6s, UAS-miro, UAS-CaMKII RNAi, UAS-CaMKII,
UAS-CaMKIIT287D, and UAS-CaMKIIT287A. UAS-CaMKII RNAi lines (38940,
47280, and 100265) were also obtained from the Vienna Drosophila Research
Center. UAS-miroT25N, UAS-miroA20V, UAS-miroE234K, and UAS-miroE234K,
E354K were kind gifts from Konrad Zinsmaier.
Generation of human TRPV4-expressing Drosophila stocks. The human
TRPV4 open reading frame (ORF) was PCR amplified from full-length human
TRPV4 cDNA in pcDNA3.1 (WT, R269C, R269C+M680K, R232C)1 using pri-
mers (GGGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGGCGGATTC
CAGCGAAGGC and GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGA
GCGGGGCGTCATCAGTCCTCCA) and recombined into pDONR 221 using BP
Clonase (Thermo Fisher Scientific). The TRPV4 ORF flanked by attL sites in the
resultant entry vectors was fully sequenced and then recombined with either
pBID29 or pTW vectors (Drosophila Gateway Vector Collection, Carnegie Insti-
tution for Science) using LR Clonase (Thermo Fisher). TRPV4(low) lines were
generated by microinjection of pBID-UASC-hTRPV4 into M{vas-int.Dm}ZH-2A,
y[1]; P{y[+]=CaryP}attP2 embryos by BestGene for PhiC31 site-specific integra-
tion at the attP2 site. TRPV4(mod) and TRPV4(high) transgenic lines were
microinjected into w1118 embryos for random P-element insertion. Transgenic
lines were identified and genetic elements mapped using conventional methods.
TRPV4 mRNA and protein expression levels in each transgenic line were deter-
mined by reverse transcription quantitative PCR (RT-qPCR) and western blot
analyses, respectively (see Methods below).
Wing expansion assay. Flies carrying the TRPV4 transgene or controls were
crossed to w1118;CCAP-GAL4/TM6B. Flies were transferred to new vials every
3–4 days. After two transfers, the P0 flies were discarded. Progeny were scored at
two times from each vial: 2 and 4 days post eclosion of the first progeny from the
cross to eclose. We selected flies carrying the CCAP-GAL4 driver and transgene of
interest and scored their wing phenotype by eye using a stereomicroscope. Flies
wings were scored as fully expanded, partially expanded, or fully unexpanded. For
analysis, partially expanded flies were counted as 0.5 normal and 0.5 unexpanded.
Flies that had phenotypic traits of virgins at the time of initial collection were set
aside and scored at least 4 hours later.
TRPV4R269C genetic modifier screen. Flies of the genotype w1118;CCAP-GAL4,
UAS-TRPV4R269C(mod)/TM6B, GAL80 were crossed to fly lines containing trans-
posable elements designed to either knockdown or overexpress endogenous Dro-
sophila genes downstream of the GAL4-binding UAS site (Supplementary Data 1
and 2). Putative modifier genes were selected based on their potential to be
druggable27, CMT genes, and other genes implicated in TRPV4 signaling. We
selected for flies carrying CCAP-GAL4, UAS-TRPV4R269C, and the screen element
and scored their wing phenotypes as described above. For experiments studying
genetic interactions with TRPV4R269C(low), flies of the genotype w1118; CCAP-
GAL4/ CyO; UAS-TRPV4r269C(low)/TM6B were used.
Climbing assays. We crossed our transgenic TRPV4(high) lines to flies carrying
the elav-GeneSwitch driver. P0 flies were transferred to new vials every 3–4 days
and were discarded after the second transfer. Progeny were allowed to develop on
standard food. Upon eclosion, we selected flies carrying TRPV4 transgenes and the
elav-GeneSwitch driver. Zero- to 3-day old flies were then transferred onto food
containing 200 μM RU486 (Sigma) at a density of 10 flies per vial. Flies were
transferred onto fresh RU486 food every 2 days. Climbing behavior was scored by
transferring flies into a climbing assay chamber which was composed of two vials
without food stacked on top of one another such that the two openings faced one
another. Lines were drawn on the vials 8 cm from either end. Once flies were in the
vial, the vial was tapped swiftly four times on the laboratory bench so as to knock
all flies to the bottom. Flies were then allowed to climb for 10 seconds at which
point we counted the number of flies above and below the 8 cm line. Flies were
allowed to rest for 1 minute and the process was repeated for a total of 10 trials per
vial of 10 flies.
RT-qPCR and western blot analyses. Analyses of TRPV4 mRNA and protein
levels were performed utilizing adult flies expressing TRPV4 variants selectively in
neurons (C155-GAL4 pan-neuronal driver). Heads were collected from adult flies
at 1–3 days post eclosion and stored at −80 °C. For quantification of TRPV4
transcript levels, heads were homogenized in Trizol (ThermoFisher) using plastic
pestles and RNA isolated using the RNeasy mini kit (Qiagen) including on-column
DNase digestion. Following cDNA conversion utilizing the High Capacity cDNA
Reverse Transcription kit (ThermoFisher), RT-qPCR was performed with the
HT7900 Real-Time PCR system (ThermoFisher) using Taqman Universal PCR
master mix and the following Taqman assays: human TRPV4 exons 3–4
(Hs01099348_m1), human TRPV4 exons 5–6 (Hs00540967_m1), human TRPV4
exons 7–8 (Hs00222101_m1), Drosophila RpII140 (Dm02134593_g1; all from
ThermoFisher). For western blot analyses, samples were lysed in RIPA buffer
(Sigma) supplemented with protease inhibitors (Cell Signaling Technology) and
sonicated. Protein lysates were resolved on 4–15% TGX gels (Bio-Rad) and
transferred to PVDF membranes (ThermoFisher). Primary antibodies used were
polyclonal rabbit anti-TRPV4 (1:500; Abcam; ab39260), monoclonal rabbit anti-β-
actin (1:1000; Cell Signaling Technology; #4970), and monoclonal mouse anti-
GAPDH (1:5000; ThermoFisher; #AM4300), followed by HRP-conjugated mouse
anti-rabbit (1:150,000; Jackson ImmunoResearch; #211-032-171) or goat anti-
mouse (1:150,000; Jackson ImmunoResearch; #211-032-171) secondary antibodies.
Membranes were developed using SuperSignal West Femto Maximum Sensitivity
Substrate (ThermoFisher) and imaged using an ImageQuant LAS 4000 system (GE
Healthcare).
Larval dissections and immunostaining. Larvae were filleted in HL3 solution to
expose the CNS and body wall, prior to fixation in 4% paraformaldehyde (PFA) in
PBS for 20 minutes at room temperature with gentle shaking. Preparations were
then washed three times over 10 minutes in PBS and blocked for 1 hour at room
temperature in 5% normal goat serum in PBS with 0.1% Triton X-100 (PBST).
Fillets were then incubated with primary antibody for 2 hours at room temperature
or overnight at 4 °C in 5% normal goat serum in PBST. Primary antibodies
included mouse anti-GFP IgG2a (1:1000, ThermoFisher, A-11120) and rabbit anti-
GFP (1:1000, ThermoFisher, A-11122). They were then washed three times over
the course of 1 hour with PBST and were then incubated for 1 hour with secondary
antibody in 5% normal goat serum in PBST. Secondary antibodies included
DyLight 488-conjugated goat anti-mouse IgG2a (1:1000, Jackson ImmunoR-
esearch, 115-285-206) and Alexa Fluor 488-conjugated goat anti-rabbit IgG
(1:1000, ThermoFisher, A-11034). Fillets were then mounted onto glass slides
in Fluoromount-G (Southern Biotech) or Vectashield (Vector Labs)
mounting media.
Ca2+ imaging in Drosophila dendritic arborization neurons. 120 h AEL third
instar larvae expressing GCaMP6s were pinned ventral side up on silicone elas-
tomer plates and dissected in external saline solution composed of: NaCl 120 mM,
KCl 3 mM, MgCl2 4 mM, CaCl2 1.5 mM, NaHCO3 10 mM, trehalose 10 mM,
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glucose 10 mM, TES 5 mM, sucrose 10 mM, and HEPES 10 mM. The osmolality
was 305 mOsm kg−1, and the pH was 7.25. Internal debris was removed with
forceps and the body wall pinned flat. Time-lapse imaging was performed under a
water-immersion objective lens (W Plan-Apochromat ×20/1.0 DIC CG= 0.17 M27
75mm) using a Zeiss LSM-700 confocal microscope. Frame rate was 1.27 Hz.
Regions of interest (ROIs) were drawn around entire somata for trace examples.
5 µm diameter circle ROIs were placed on brightest part of each soma to calculate
responses to 40 nM GSK101 or DMSO, which were added directly to the
recording media.
Imaging of sponataneous calcium transients with GCaMP5-myr was performed
on a Zeiss Axio-Observer widefield micrscope using a ×63 oil immersion lense.
Larvae were dissected ventral side down in HL3 with 2.0 mM Ca2+ on a sylgard
block. After removal of the internal tissues, the sylgard block to which the fillet was
pinned was inverted and placed down on a large, circular glass coverslip such that
the fillet rested against the coverslip while immersed in HL3. Images were acquired
at a rate of four frames per second for one minute with excitation from a 475 nm
LED light source. The acquired image series were then blinded, and an
experimenter who was not involved in image acquisition counted the number of
calcium transients, defined as clear, observable increases in GCaMP5-myr
fluorescence intensity throughout each movie.
Mouse husbandry. All mice used in this study were housed and handled according
to protocols approved by the Animal Care and Use Committee of Johns Hopkins
University School of Medicine.
Mouse trigeminal neuron isolation and culture. Six to 10 week-old C57BL/6 J
mice were deeply anesthetized with isoflurane and killed by cervical dislocation.
The bilateral trigeminal ganglia were then harvested and dissociated via con-
secutive incubations in Hibernate (Brain Bits) with papain (37 °C 20 min, gentle
agitation at 10 min) followed by collagenase/dispase (37 °C 20min, gentle agitation
at 10 min)69. After enzyme incubations, harvested ganglia were gently titruated 2–3
time with a P1000 pipette tip followed by an additional 2–3 passes through a P200
pipette tip. Titurated ganglia were carefully overlayed on a Percoll gradient and
centrifuged at 1500 × g for 20 min. The top layer was carefully removed and cen-
trifuged for 10 min at 1000 × g. Trigeminal neurons were plated on poly-L-orni-
thine and collagen/laminin coated eight-well Borosilicate coverglass imaging
chambers (ThermoFisher). Neurons were transduced with virus carrying GFP,
TRPV4WT-EGFP, or TRPV4R269C-EGFP 24 hours after plating. Experiments were
performed 72 hours after viral transduction.
Lentivirus production. TRPV4WT and TRPV4R269C with a C-terminal EGFP tag
in pcDNA3.1 were subcloned into the lentivirus transfer vector FUGW (gift from
David Baltimore, Addgene plasmid #14883) (PMID 11786607). In brief, TRPV4-
EGFP was PCR amplified (Forward primer: CTTGGGCTGCAGGTCGACTCTA
GAGATGGCGGATTCCAGCGAAG, Reverse primer: TTGATTATCGATAAGC
TTGATATCGTTACTTGTACAGCTCGTCCATG) and subcloned into the EcoRI
and BamHI restriction sites of the FUGW plasmid using the Gibson Assembly
Cloning Kit (New England Biolabs). Lentivirus was produced by transfecting
HEK293T cells with second generation packaging vectors pCMV-VSV-G and
pCMV-dR8.91 (gifts from Jeffrey Rothstein) along with FUGW TRPV4-EGFP
(WT or R269C). HEK293T cells were transfected using polyethylenimine (PEI) and
virus-containing media was harvested at 48 and 72 hours post transfection and
concentrated using Lenti-X Concentrator (Takara).
Trigeminal neuron Ca2+ imaging. Virally transduced trigeminal neurons and
50B11 cells were loaded with the ratiometric Ca2+ indicator Fura-2AM (Ther-
moFisher) for 1 hour at 37 °C per the manufacturer’s instructions. Ca2+ imaging
was performed on a Zeiss AxioObserver.Z1 inverted microscope equipped with a
Lambda DG-4 (Sutter Instrument Company) wavelength switcher. Prior to Ca2+
imaging of trigeminal neurons, a single channel GFP image was acquired to
measure TRPV4 expression within individual neurons. Cells were imaged at
340 nm and 380 nm excitation at three 10 second intervals to acquire a baseline
fluorescence measurement prior to the application of the TRPV4-selective agonist
GSK1016790A (MilliporeSigma), after which cells were imaged for ~4 minutes at a
rate of one frame per 10 seconds. Baseline calcium was determined at t=−10 s, the
timepoint immediately prior to addition of GSK1016790A. The CaMKII inhibitor
KN-93 and its inactive analog KN-92 (Cayman Chemical) were used at 10 μM and
applied for 4 hours prior to imaging. AIP (MilliporeSigma) was used at 10 μM and
applied two hours prior to imaging.
Trigeminal neuron fixation and immunostaining. Coverslips with transduced
trigeminal neurons were washed three times quickly with PBS. Neurons were then
fixed for 15 minutes at room temperature in 4% PFA. PFA was removed and
coverslips were rinsed with PBS. Neurons were then permeabilized with PBS plus
0.1% TritonX-100 (PBST) for 10 minutes. Coverslips were then washed briefly with
PBS and incubated with mouse anti-GFP IgG2a (1:1000, ThermoFisher, A-11122)
and chicken anti-TUJ1 (1:1000) antibodies diluted in blocking buffer (4% normal
goat serum in PBST) overnight with gentle shaking at 4 °C. Coverslips were then
washed six times, 10 minutes each in PBST and were then incubated with DyLight
488-conjugated goat anti-mouse IgG2a (1:1000, Jackson ImmunoResearch, 115-
285-206) and Alexa Fluor 555-conjugated goat anti-chicken (1:1000, Thermo-
Fisher, A-21437) secondary antibodies in blocking buffer for 1 hour at room
temperature with gentle shaking. Coverslips were then washed six times, 10 min-
utes each in PBST. Coverslips were than mounted with VectaShield+DAPI (Vector
Labs) and sealed with nail polish.
Confocal microscopy-fixed imaging. Slides were imaged on a Zeiss 800 LSM
confocal laser scanning microscope with a ×20 air, ×40 oil immersion, or ×63 oil
immersion objective. Image acquisition parameters were kept uniform across all
samples in a given experiment.
Confocal microscopy and live imaging of trigeminal neurons. Transduced tri-
geminal neurons were incubated for 2 hours with 10 μM KN-92 or KN-93. Neu-
rons were then incubated for 20 minutes with ER-Tracker Red (0.5 μM,
ThermoFisher, E34250) diluted in artificial cerebrospinal fluid (aCSF) with either
KN-92 or KN-93. Wells were then washed quickly three times with pre-warmed
aCSF, and cells were finally placed in pre-warmed aCSF with either 10 μm KN-92
or 10 μm KN-93. Neurons were imaged on a Zeiss 800 LSM confocal laser
scanning microscope with a ×63 Plan-apochromat oil immersion lens.
Live cell imaging of axonal transport in Drosophila. Mito-GFP was used to label
mitochondria and was expressed in C4da neurons along with TRPV4 using the
ppk-GAL4 driver. Wandering third instar larvae were dissected in HL3 solution
with 0.6 mM Ca2+ and 4 mM glutamate as described70. Larvae were then mounted
in HL3 solution on glass slides with the coverslip secured via dental glue (Surgi-
dent, #50092189). For experiments involving drug treatments, drug was added to
the dissection media and allowed to incubate at least 5 minutes prior to image
acquisition. Imaging was performed on a Zeiss 800 LSM with a ×63 oil objective.
Image series of C4da neuron axons were captured in a single focal plane at an
acquisition rate of 1 frame/second for 2 minutes, in a 200 μm~500 μm window
from the cell body in abnominal segements A6 and A7. Movement dynamics were
calculated by tracking the position of individual mitochondria frame by frame in
ImageJ as previously described70. Since one pixel represents 0.198 μm in our image
acquisition, only net velocities >0.2 μm/s with more than three consecutive frames
in one direction were considered as anterograde or retrograde. Moving mito-
chondria that could be tracked for >60 frames continuously were considered for
measuring mitochondrial run length or duty cycle, and representative kymographs
were generated from the acquired time-lapse images using Zeiss Zen Blue
2.3 software. For experiments involving GSK1016790A, larvae were bathed in
recording media which contained GSK1016790A during mounting for imaging.
For experiments involving GSK2193874, larvae were raised on food with 10 μM
GSK2193874 due to the observed insensitivity of TRPV4R269C to this compound in
electrophysiologic recordings (Fig. 4c). Larvae were also bathed in recording media
with 10 μM GSK2193874 during dissection and mounting for imaging.
Electrophysiological recordings of NCCAP. Experiments were performed on 1–3-
day old adult female flies. Perforated patch-clamp recordings with β-escin were
performed as previously described with minor modifications25, in order to measure
action potentials (APs) from CCAP neurons located in the brain. Brains were
removed and dissected in a Drosophila physiological saline solution (101 mM NaCl,
3 mM KCl, 1 mM CaCl2, 4 mM MgCl2, 1.25 mM NaH2PO4, 20.7 mM NaHCO3,
and 5 mM glucose; pH 7.2), which was pre-bubbled with 95% O2 and 5% CO2. To
better visualize the recording site, the perineuronal sheath surrounding the brain
was focally and carefully removed after treating with an enzymatic cocktail, col-
lagenase (0.4 mg/ml) and dispase (0.8 mg/ml), at 22 °C for 1 minute and cleaning
with a small stream of saline pressure-ejected from a large diameter pipette using a
1 mL syringe. In addition, prior to recording, cell surfaces were cleaned with saline
pressure-ejected from a small diameter pipette, using a 1 ml syringe connected to
the pipette holder. The recording chamber was placed on an X–Y stage platform
(PP-3185-00; Scientifica, UK). The cell bodies of the targeted CCAP neurons were
visualized with CD8:GFP fluorescence on a fixed-stage upright microscope
(BX51WI; Olympus, Japan) and viewed with a ×40 water-immersion objective lens
(LUMPlanFl, NA: 0.8, Olympus). Patch pipettes (8–12MΩ) were fashioned from
borosilicate glass capillaries without filaments (OD/ID: 1.2/0.68 mm, 627500, A-M
systems, WA) using a Flaming-Brown puller (P1000; Sutter Instrument), and
further polished with a MF200 microforge (WPI) prior to filling with the internal
pipette solution (102 mM potassium gluconate, 0.085 mM CaCl2, 0.94 mM EGTA,
8.5 mM HEPES, 4 mM Mg-ATP, 0.5 mM Na-GTP, 17 mM NaCl; pH 7.2). Biocytin
hydrazide (13 mM; ThermoFisher) was added to the pipette solution before the
recording. Recordings were acquired with an Axopatch 200B amplifier (Molecular
Devices) and sampled with a Digidata 1440 A interface (Molecular Devices). These
devices were controlled via pCLAMP 10 software (Molecular Devices). The signals
were sampled at 20 kHz and low-pass filtered at 2 kHz. Junction potentials were
nullified prior to high-resistance (GΩ) seal formation. Cells showing evidence of
“mechanical” breakthrough, as assessed by the abrupt generation of a large capa-
citance transient (as opposed to the more progressive, gradual one generated by
chemical perforation) were excluded. One CCAP neuron per brain was recorded.
During the recording, the bath solution was slowly but continuously exchanged
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with fresh saline by means of a gravity-driven system (approximate flow rate of
1–2 ml/min). The mean firing rate of spontaneous APs and RMP were determined
by the mean value of voltage during zero-holding current (0 pA as Ihold) gap-free
recording. For quantifying intrinsic membrane excitability, APs were elicited in
response to current injections with 300 ms stepping pulses at 20 pA increments up
to 100 pA. Electrophysiological analysis of both spontaneous APs and evoked APs
was performed using custom MATLAB-based software. APs were detected auto-
matically by identification of local maxima and were then manually curated to
remove excitatory post-synaptic potentials using minimum voltage threshold cri-
teria. Frequency of detected APs was quantified as mean firing rate during current
injection. The current threshold (minimum current to evoke spiking) and the slope
of the f–I curve were determined by linear regression of the curve from the point of
initial spiking. To analyze subthreshold membrane potential dynamics as Δramp,
spontaneous APs were first removed from the raw traces by introducing median
filter and smoothing using a 7–18 ms (depending on spike width) moving average.
Δramp was then quantified as the difference between the most depolarized value
and the most hyperpolarized value during the recording.
Internal Ca2+ chelation experiments were carried out by intracellular perfusion
with the Ca2+ chelator, BAPTA. For experiments with intracellular perfusion of
BAPTA, a conventional whole-cell patch technique was used. Patch pipettes filled
with internal pipette solution containing 5 mM BAPTA were brought up to the cell
bodies. After GΩ seal formation, the patched membrane was ruptured by applying
negative pressure. Data acquisitions of membrane potential were initiated 5 min
following the rupture of the membrane.
GSK2193874 was prepared as a 20 mM stock solution dissolved in DMSO, and
this stock was mixed into Drosophila physiological saline solution at a final
concentration of 100 nM, 500 nM, or 10 μM. To achieve substantial penetration of
the drug into the whole-brain tissue preparation, data acquisitions of membrane
potential were carried out after 60 min bath application of the drug as
preincubation period. During the preincubation period, 95% O2 and 5% CO2 pre-
bubbled Drosophila physiological saline solution containing the drug was
continuously perfused by Peristaltic pump (MINIPULS 3, Gilson) with flow rate of
2–3 ml/min. Recovery was not tested because of the considerable amount of time
required to wash out drugs, in particular hydrophobic compounds, such as
GSK2193874.
After recording the physiological responses of NCCAP, biocytin hydrazide was
iontophoresed into the cell with a constant hyperpolarizing current of 0.9–1.2 nA
passed for at least 5 minutes. The brain was then fixed in 4% PFA in PBS overnight
at 4 °C. After washing for 1 hour in several changes of PBST (0.3% Triton X-100 in
PBS) at room temperature, the brain was incubated with a mouse anti-GFP
antibody (Invitrogen, 1:200) for 16-40 hours on a shaker at 4 °C, followed by
incubation with an Alexa Fluor 488-conjugated goat anti-mouse (Invitrogen,
1:1000) secondary antibody and Alexa Fluor 568-conjugated streptavidin
(Invitrogen, 1:100) for 24–40 hours on a shaker at 4 °C. After a 1 hour wash,
samples were cleared in 70% glycerol in PBS for 5 minutes at room temperature
and then mounted in Vectashield (Vector Labs). Recorded CCAP neurons were
imaged using a confocal imaging system (LSM-700; Carl Zeiss).
Image analysis. Fluorescent images were analyzed using ImageJ (NIH) or Imaris
(Bitplane, Zurich, Switzerland). Synaptic area measurements were acquired in
ImageJ using the Analyze Particles tool. In brief, confocal stacks were converted to
maximum intensity projections and background fluorescence subtracted using the
Math function. The image was then thresholded and an ROI was drawn around the
segment to be measured and CD8-GFP positive area was measured using the
Analyze Particles tool. Dendritic branching was measured in ImageJ or Imaris. In
ImageJ confocal stacks were converted to maximum intensity projections, back-
ground fluorescence was then subtracted and the image was thresholded and
converted to a binary image. Branching was measured using the Sholl analysis tool.
In Imaris, dendrites were semi-automatically traced using the Filaments tool. In
brief, images were thresholded to identify the center and seed points, filaments
were then manually evaluated and incorrected tracings were removed and missing
tracings were added. Branching was assessed using the Sholl branching tool. In
either software, the spacing of the Sholl radii was 10 μm.
Statistical analysis. Statistical analyses were performed in Prism 7.0 (GraphPad).
For normally distributed datasets comparing summative statistics (e.g., mean) an
unpaired t test, or a one- or two-way analysis of variance (ANOVA) was used, as
appropriate. For data sets of repeated measures (e.g., calcium imaging over time), a
two-way ANOVA with a Geisser-Greenhouse correction was used. If the ANOVA
detected a significant interaction (α= 0.05), Tukey’s post hoc test was performed to
identify which groups were significantly different. The level of significance is
indicated as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Sample sizes (“n”)
and indicators of statistical significance are noted within the Figure legends. For all
graphs of Drosophila wing expansion, data are presented as a percentage of whole.
The error bars in those graphs depict the 95% confidence intervals that were
calculated using the Wilson/Brown method. A Χ2 test across all experimental
groups was performed to test for the presence of any interaction. Pairwise Fisher’s
exact tests were then performed between relevant groups to assess for significant
inter-group differences.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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